Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in pregnant women with COVID-19 (HyPreC)
NCT04354441Phase 2Withdrawn
- Sponsor
- Jewish General Hospital
- Start
- May 2020
- Primary completion
- May 2020
01
Overview
Phase 2, randomised, double-blind trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by Jewish General Hospital. Primary endpoint: COVID-19-related hospital admissions. Planned start May 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04354441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354441.